Poxel S.A. (EPA: POXEL)
France
· Delayed Price · Currency is EUR 0.234
-0.001 (-0.21%)
Nov 20, 2024, 5:35 PM CET
Poxel Revenue
In the year 2023, Poxel had annual revenue of 1.98M EUR with 193.92% growth. Poxel had revenue of 1.03M in the half year ending December 31, 2023, with 734.15% growth.
Revenue
1.98M
Revenue Growth
+193.92%
P/S Ratio
3.95
Revenue / Employee
330.17K
Employees
6
Market Cap
12.44M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1.98M | 1.31M | 193.92% |
| Dec 31, 2022 | 674.00K | -12.72M | -94.97% |
| Dec 31, 2021 | 13.40M | 6.59M | 96.84% |
| Dec 31, 2020 | 6.81M | -19.75M | -74.37% |
| Dec 31, 2019 | 26.56M | -35.82M | -57.43% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 48.45B |
| EssilorLuxottica Société anonyme | 25.83B |
| Sartorius Stedim Biotech S.A. | 2.74B |
| bioMérieux S.A. | 3.81B |
| Ipsen S.A. | 3.44B |
| Eurofins Scientific SE | 6.72B |
| Virbac SA | 1.34B |
| Ramsay Générale de Santé SA | 5.01B |
Poxel News
- 14 days ago - Poxel Announces that its Annual General Meeting Will Be Held on November 28, 2024, at 9 am CET and the Availability of Preparatory Documents - Business Wire
- 6 weeks ago - Poxel SA (STU:7PO) Full Year 2023 Earnings Call Highlights: Strategic Moves and Financial Challenges - GuruFocus
- 7 weeks ago - Poxel Reports Financial Results for Full Year 2023 and Provides Corporate Update - Business Wire
- 7 weeks ago - Poxel Announces Agreement with OrbiMed to Monetize a portion of TWYMEEG® Royalties for USD 50 million - Business Wire
- 2 months ago - Poxel Reports Revenue for the Second Quarter and First Half 2024 and Provides Corporate Update - Business Wire
- 3 months ago - Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG® for the Treatment of Type 2 Diabetes in Japan - Business Wire
- 4 months ago - Poxel Provides an Update on Its Financial Position for the Second Quarter and First Half of 2024 and Announces the Rescheduling of Its Annual General Meeting - Business Wire
- 6 months ago - Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update - Business Wire